Eyecare

In a study, both common and rare HMGCR variants were associated with an increased risk for cataract.

Regeneron is seeking an additional dosing regimen with a longer-term interval between doses. The PDUFA date is Feb. 28, 2023.

Xipere became commercially available in March 2022. It is the first therapy for patients with macular edema that provides a targeted delivery to the retina.

A biomarker used in kidney disease screening has potential to identify people with sight-threatening diabetic retinopathy.

Perfluorohexyloctane prevents excessive tear evaporation and has the ability to restores tear film balance. A new drug application is expected to be filed this year.

Byooviz, the first FDA approved ophthalmology biosimilar for macular degeneration, will be priced 40% lower than the reference product. It will be commercially available on July 1, 2022.

If approved, Orasis’ low-dose pilocarpine would be the second product that improves presbyopia, which is the age-related loss of clear up-close vision. The company plans to submit an NDA in the second half of the year.

Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.

Phase 3 trials show CSF-1, a low-dose pilocarpine, met clinical endpoints for improving presbyopia, or age-related blurry vision.

Xipere is a targeted treatment that is delivered via an injection to the back of the eye to treat macular edema associated with uveitis, a form of eye inflammation.

Cystaran is a topical ophthalmic therapy that is used to treat a rare genetic disorder.

This expands commercial coverage to 118 million lives and Medicare coverage to 7.1 million lives.

The use of digital devices has surged significantly as people spend more time at home, with Americans logging an average of 13 hours per day watching screens. That compares to between seven and 10 hours per day before the COVID-19 pandemic started, with the increase in screen time likely contributing to more exposure to blue light.

Vuity, developed by Allergan, is a once-daily eye drop to treat presbyopia.

Xipere is delivered via an injection to the back of the eye to treat macular edema associated with uveitis, a form of eye inflammation.

Genentech’s Susvimo is a refillable implant that delivers medication continuously for up to six months.

Tyrvaya is a twice daily nasal spray, a first for the treatment of dry eye disease.

Biogen/Samsung Bioepis’ Byooviz is a biosimilar of Genentech’s Lucentis.

The American Academy of Ophthalmology says biosimilar alternatives to Avastin have never been tested in the eye.

Diana Do, MD, and Steven Peskin, MD, MBA, FACP, discuss unmet needs and future approaches to treatment in wet AMD.

Steven Peskin, MD, MBA, FACP, provides insight into managed care considerations of wet AMD including clinical evidence evaluation, formulary management, and value-based agreements.

Diana Do, MD, discusses outcomes of interest for anti-VEGF agents, clinical evidence supporting the treat-and-extend approach, and strategies to overcome financial barriers in wet AMD.

Diana Do, MD, provides insight into anti-VEGF treatment selection for individual patients, evaluation of patient response to therapy, and considerations for switching of agents.

Diana Do, MD, provides an overview of available anti-VEGF agents used in the treatment of wet AMD and Steven Peskin, MD, MBA, FACP, discusses management strategies employed with these agents.

Diana Do, MD, and Steven Peskin, MD, MBA, FACP, discuss overtreatment and undertreatment in wet AMD in addition to the risks associated with delays in therapy.